Published

PDE4B Inhibition and Psilocybin as Promising Approaches for Treating Methamphetamine Use Disorder: Preclinical Evidence From Rat Models (Abstract ID: 232554)

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: The Journal of Pharmacology and Experimental Therapeutics
Date: 2026-05-01
Source: Crossref
DOI: 10.1016/j.jpet.2026.104282
PubMed: Unavailable

Authors

Hayduk Sean Stringer Amy Zagorski Satoria Ward Sara Jane

Watch author

Derived topics and classifications

psilocybin Animal Study Animal Study

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

PDE4B Inhibition and Psilocybin as Promising Approaches for Treating Methamphetamine Use Disorder: Preclinical Evidence From Rat Models (Abstract ID: 232554)2026-05-01

Related papers

Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto RatsPsychedelic Medicine · 2025-12-16 ‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injuryInternal Medicine Journal · 2026-01-01 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01 Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot StudyPsychedelic Medicine · 2026-02-03 The Rise of Psilocybin Use in the United States: A Multisource Observational Study.Annals of internal medicine · 2025-07-01 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06 Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialCommunications Medicine · 2026-07-30